What is albiglutide, and what is it used for?
Albiglutide (brand name Albiglutide is often referenced in connection with the diabetes medicine Tanzeum) is a GLP-1 receptor agonist used to improve blood sugar control in adults with type 2 diabetes. It works by helping the pancreas release insulin in response to meals and by slowing stomach emptying, which can reduce post-meal glucose spikes.
Why do people search for albiglutide now (status and market availability)?
People often look up albiglutide because its market presence changed over time. For current availability and the latest manufacturer/prescriber information, check drug listings from your country’s regulator or major pharmacy databases.
What happened to Tanzeum (albiglutide)?
Albiglutide is strongly associated with Tanzeum, and the drug’s commercial path has shifted since its introduction. If you’re researching whether it’s still sold, discontinued, or restricted, the most reliable answers come from regulator notices and current formulary status in your location.
How is albiglutide different from other GLP-1 drugs?
Albiglutide is in the same drug class as other GLP-1 receptor agonists (for example, weekly and daily options). The main practical differences people compare are usually:
- dosing frequency (some GLP-1 products are weekly, others are daily)
- side-effect profile and tolerability
- coverage and cost, which vary by insurer and country
What patents and exclusivity questions come up for albiglutide?
Searchers commonly ask when competitors can enter and when exclusivity ends. For patent-by-patent tracking, including filings and timelines, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/
What side effects are people concerned about with albiglutide?
Like other GLP-1 receptor agonists, albiglutide is typically associated with:
- gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation)
- hypoglycemia risk mainly when used with other glucose-lowering drugs such as insulin or sulfonylureas
- warnings that can apply across the class (for example, pancreatitis and gallbladder-related issues are often discussed for GLP-1 medicines)
Can patients switch from albiglutide to another GLP-1?
If albiglutide is not available where you live or your clinician stops it, the usual next step is switching to an alternative GLP-1 receptor agonist or another diabetes therapy based on your:
- A1C and glucose pattern
- kidney function
- history of side effects (especially GI intolerance)
- insurance coverage and injection preferences (weekly vs daily)
If you tell me your country (and whether you’re asking for diabetes treatment info or patent/availability research), I can narrow this to the most relevant, up-to-date details.
Sources
- DrugPatentWatch.com - albiglutide (Tanzeum) patent tracking